Actively Recruiting
Serplulimab Combined With FOLFIRI and Bevacizumab in the Treatment of Colon Cancer Peritoneal Metastases
Led by Second Affiliated Hospital, School of Medicine, Zhejiang University · Updated on 2023-02-24
30
Participants Needed
1
Research Sites
261 weeks
Total Duration
On this page
Sponsors
S
Second Affiliated Hospital, School of Medicine, Zhejiang University
Lead Sponsor
C
Changxing People's Hospital
Collaborating Sponsor
AI-Summary
What this Trial Is About
Multicentric randomised trial. The goal of this clinical research study is to evaluate the efficacy and safety of serplulimab combined with FOLFIRI+bevacizumab in the treatment of pMMR/Ras/BRAF wild-type unresectable peritoneal metastasis of colon cancer.
CONDITIONS
Official Title
Serplulimab Combined With FOLFIRI and Bevacizumab in the Treatment of Colon Cancer Peritoneal Metastases
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Colon cancer confirmed by histology with pMMR/MSS and RAS/BRAF wild-type gene status
- Imaging shows peritoneal metastasis
- Peritoneal metastatic carcinoma not able to reach CC0/1 by surgery
- Age between 18 and 75 years
- Performance status (ECOG) 0, 1, or 2 with life expectancy over 12 weeks
- Adequate kidney and bone marrow function: leukocytes 3,000/microL; absolute neutrophil count 1,500/microL; platelets 100,000/Ul; serum creatinine 1.5 mg/dL
- Liver function with AST/ALT 5 times upper normal limit
- Able to tolerate immunotherapy, chemotherapy, and surgery
- Informed consent signed before any trial procedures
You will not qualify if you...
- Age younger than 18 years or older than 75 years
- Cancer originating outside the colon
- History of cancer (other than certain skin or cervical cancers) with recurrence within the past 5 years
- Known positive for HIV, Hepatitis B, or Hepatitis C
- Pregnant or likely to become pregnant
- Under legal guardianship
- Unable to follow study or follow-up procedures
- Known life-threatening or severe allergic reaction to the chemotherapy used in this trial
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Changxing County People's Hospital
Huzhou, Zhejiang, China, 330522
Actively Recruiting
Research Team
L
Lifeng Sun
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here